Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant energy intake study in obese patients
NCT00481923Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in obesity (4 arms), sponsored by Sanofi. Primary endpoint: Absolute change from baseline in energy intake during ad-libitum dinner of the high-fat probe day. Started May 2004; status: completed.
02
Drugs
rimonabant
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00481923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481923.